Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Eugenia Abaleke, Mustafa Abbas, Sadia Abbasi, +4966

The Lancet

Long CovidAntimicrobial StewardshipAntibioticsClinical InfectionPlatform Trial +5

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas, +4969

The Lancet

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas, +4973

The Lancet

Covid-19 PandemicAntiviral TherapyClinical TrialsPlatform TrialMedicine +1

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas, +4972

The Lancet

Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial

Martin Dennis, Gillian Mead, John Forbes, +1286

The Lancet

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Rustam Al‐Shahi Salman, M. J. S. Dennis, PAG Sandercock, +942

The Lancet

Impact of Mechanical Activation, Scar, and Electrical Timing on Cardiac Resynchronization Therapy Response and Clinical Outcomes

Kenneth C. Bilchick, Sujith Kuruvilla, Yasmin S. Hamirani, +14

Journal of the American College of Cardiology

Electrical TimingHeart FailureCardiac AnaesthesiaDevice TherapyCardiovascular Disease +8

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas, +4972

The Lancet

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Rustam Al‐Shahi Salman, David Minks, Dipayan Mitra, +960

The Lancet Neurology

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge, Natalie Staplin, KJ Mayne, +1637

The Lancet Diabetes & Endocrinology